Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio Inc (GRI) is a clinical-stage biotechnology pioneer advancing novel NKT cell-targeted therapies for inflammatory and autoimmune disorders. This dedicated news hub provides investors and industry stakeholders with essential updates on therapeutic developments, financial disclosures, and strategic milestones.
Access timely reports on GRI-0621 (oral inhibitor for liver disease/dermatology) and GRI-0803 (autoimmune candidate), including clinical trial progress, regulatory filings, and peer-reviewed research. Our curated collection features press releases, earnings call transcripts, and partnership announcements directly from the company and verified sources.
Key coverage areas include phase trial results, intellectual property updates, executive leadership changes, and scientific conference presentations. Bookmark this page to monitor GRI Bio's progress in developing oral therapies that modulate immune responses through its proprietary NKT cell platform.
GRI Bio (NASDAQ: GRI) reported positive Phase 2a flow cytometry data for GRI-0621 in idiopathic pulmonary fibrosis (IPF). After 12 weeks, treated subjects showed iNKT inhibition, increased TCR expression, higher anti-fibrotic IFN-γ and reductions in IL-4, IL-13, IL-17A, IL-22 and TGF-β in BAL and PBMC samples versus baseline or placebo.
The randomized, double-blind 2:1 study enrolled 35 subjects (4.5mg daily or placebo) with an 8-subject BAL sub-study. The trial met its primary safety/tolerability endpoint and reported exploratory signals of collagen turnover, lung repair and more subjects with no FVC decline at 12 weeks versus standard of care. Company completed a December 2025 public offering and reports stockholders' equity above the Nasdaq $2.5M minimum.
GRI Bio (NASDAQ: GRI) closed a public offering on Dec 12, 2025 of 10,666,667 common shares (or equivalents) with accompanying Series F warrants at a combined public offering price of $0.75 per share and warrant.
Aggregate gross proceeds to the company were approximately $8.0 million before placement agent fees and offering expenses. The Series F warrants are exercisable immediately at $0.75 per share, expire five years after issuance, and could generate approximately $8.0 million additional gross proceeds if fully exercised. H.C. Wainwright acted as exclusive placement agent. The company intends to use net proceeds for product candidate development, working capital and general corporate purposes. The offering was made under an S-1 declared effective by the SEC on Dec 11, 2025.
GRI Bio (NASDAQ: GRI) priced a best efforts public offering of 10,666,667 common shares (or equivalents) and accompanying Series F warrants at a combined public offering price of $0.75 per share with attached warrant. The Series F Warrants have a $0.75 exercise price, are exercisable immediately and expire five years after issuance. Closing is expected on or about December 12, 2025. Gross proceeds are expected to be approximately $8,000,000, with potential additional proceeds of approximately $8,000,000 if warrants are fully exercised. Proceeds are intended for product candidate development, working capital and general corporate purposes. The offering is made under an effective Form S-1 declared by the SEC on December 11, 2025.
GRI Bio (NASDAQ: GRI) announced positive topline results from its Phase 2a GRI-0621-IPF-02 study in idiopathic pulmonary fibrosis (IPF) on December 10, 2025. The 12-week, randomized (2:1), placebo-controlled trial enrolled 35 subjects and met its primary safety endpoint with no drug-related severe or serious adverse events.
Key secondary and exploratory findings included biomarker shifts consistent with fibrosis resolution and alveolar basement membrane repair (PRO-C6 -3% vs +12% placebo; C6M +6% vs -3% placebo; PRO-C4 +9% vs -2% placebo) and placebo-adjusted increases in forced vital capacity (+99 ml overall; +139 ml in the subgroup on standard of care). Overall, 39% of GRI-0621 subjects had increased FVC at 12 weeks.
GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim lung function data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The data showed no decline in forced vital capacity (FVC) at 6 weeks compared to baseline in treated patients.
The study, involving 24 subjects, demonstrated positive biomarker changes suggesting anti-fibrotic effects, including decreased fibrosis formation markers and increased fibrosis resolution markers. The Independent Data Monitoring Committee (IDMC) reported no safety concerns and recommended continuing the study as planned.
The Phase 2a trial has fully enrolled approximately 35 subjects, randomized 2:1 to receive GRI-0621 4.5mg or placebo. Topline results are expected in Q3 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Marc Hertz will deliver a presentation on September 9, 2025, at 3:00 PM ET in New York. Management will also conduct one-on-one meetings with qualified investors during the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days after the event.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.
The virtual presentation will be delivered by CEO Marc Hertz, PhD on Wednesday, August 20, 2025 at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators, announced CEO Marc Hertz's participation in a Virtual Investor "What This Means" segment. During the presentation, Dr. Hertz discussed the company's recently announced 6-week interim biomarker data from their ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (IPF).
GRI Bio (NASDAQ: GRI) has reported encouraging 6-week interim biomarker data from its Phase 2a study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) treatment. The study, which has completed enrollment of approximately 35 subjects, showed that GRI-0621 treated patients demonstrated favorable reduction in fibrogenesis biomarkers and increased basement membrane remodeling.
The Independent Data Monitoring Committee (IDMC) has recommended continuing the study as planned, noting no safety concerns in the data reviewed. The trial remains blinded, with patients randomized in a 2:1 ratio for GRI-0621 4.5mg or placebo. The company expects to report topline results in Q3 2025, with additional pulmonary function test data expected in the coming weeks.
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Marc Hertz, PhD shared insights about his leadership journey, his commitment to the company, and his enthusiasm for GRI Bio's development programs. The presentation is now available for viewing on virtualinvestorco.com and the company's investor relations website.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
